circPDSS1 regulates the invasion, migration and apoptosis of hepatocellular carcinoma cells by targeting miR-1298

Abstract

Abstract: Objective To investigate the effect of circular RNA PDSS1 (circPDSS1) on apoptosis, migration and invasion of liver cancer cells and its mechanism. Methods The expression of circPDSS1 and miR-1298 in liver cancer tissues and adjacent tissues were detected by real-time fluorescence quantitative PCR (RT-qPCR). Dual luciferase reporter gene experiment and RT-qPCR were used to confirm the targeted regulation of circPDSS1 on miR-1298. CircPDSS1 small interfering RNA (si-circPDSS1), miR-1298 mimics, si-circPDSS1+ miR-1298 inhibitor (anti-miR-1298) were transfected into liver cancer cell MHCC97H, respectively. Apoptosis was detected by flow cytometry, and cell migration and invasion were detected by transwell assays. Results Compared with adjacent tissues, the expression of circPDSS1 in liver cancer tissues was significantly increased (3.41±0.33 vs 1.00±0.06), while the expression of miR-1298 was significantly reduced (0.42±0.04 vs 1.00±0.07, P<0.05). circPDSS1 targeted and negatively regulated miR-1298 expression. After inhibiting the expression of circPDSS1, the apoptosis rate of MHCC97H cells was significantly increased (22.71±2.19% vs 6.02±0.05%), while the number of migrating (55.72±4.78 vs 101.86±9.65) and invasive (41.24±3.80 vs 85.71±7.57) cells were significantly decreased (P<0.05). After overexpression of miR-1298, the apoptosis rate of MHCC97H cells was significantly increased (18.67±1.06% vs 7.08±0.69%), while the cell numbers of migrating (61.11±5.54 vs 107.15±10.96) and invading (50.05±4.22 vs 88.57±7.96) were significantly decreased (P<0.05). Compared with the inhibition of circPDSS1, the apoptosis rate (11.68±1.24% vs 23.31±2.84%) of MHCC97H after the inhibition of miR-1298 and circPDSS1 was significantly decreased, while the cell numbers of migrating (86.59±7.44 vs 54.59±4.78) and invading (76.01±6.33 vs 39.91±3.73) were significantly increased (P<0.05). Conclusion Inhibiting the expression of circPDSS1 can reduce the migration and invasion ability of liver cancer cells and induce apoptosis. The mechanism is related to the targeted regulation of miR-1298.

Key words: circPDSS1, liver cancer, migration and invasion, apoptosis, miR-1298

LI Min, WU Xing-gui, ZHU Jun-hua. circPDSS1 regulates the invasion, migration and apoptosis of hepatocellular carcinoma cells by targeting miR-1298[J]. Chinese Hepatolgy, 2021, 26(9): 1011-1015.

References

[1] Kim NG, Nguyen PP, Dang H, et al. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: a real-world experience from 1998 to 2015. Cancer, 2018, 124: 2588-2598.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391: 1301-1314.
[3] Vo JN, Cieslik M, Zhang Y, et al. The Landscape of Circular RNA in Cancer. Cell, 2019, 176: 869-881.
[4] Kristensen LS, Hansen TB, Ven? MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene, 2018, 37: 555-565.
[5] Ouyang Y, Li Y, Huang Y, et al. CircRNA circPDSS1 promotes the gastric cancer progression by sponging miR-186-5p and modulating NEK2. J Cell Physiol, 2019, 234: 10458-10469.
[6] Qiu ZK, Liu N, Zhao SF, et al. MiR-1298 expression correlates with prognosis and inhibits cell proliferation and invasion of gastric cancer. Eur Rev Med Pharmacol Sci, 2018, 22: 1672-1679.
[7] Du Z, Wu J, Wang J, et al. MicroRNA-1298 is downregulated in non-small cell lung cancer and suppresses tumor progression in tumor cells. Diagn Pathol, 2019, 14: 132-137.
[8] Yu Q, Liu P, Han G, et al. CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16. Biosci Rep, 2020, 40: BSR20191961.
[9] Wang X, Yang B, She Y, et al. The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem, 2018, 119: 7790-7799.
[10] Wang R, Ke ZF, Wang F, et al. GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem, 2015, 35: 969-982.
[11] Yu J, Xu QG, Wang ZG, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol, 2018, 68: 1214-1227.
[12] Zhou Y, Dang J, Chang KY, et al. miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. Cancer Res, 2016, 76: 5777-5787.
[13] Li G, Sun L, Mu Z, et al. MicroRNA-1298-5p inhibits cell proliferation and the invasiveness of bladder cancer cells via down-regulation of connexin 43. Biochem Cell Biol, 2020, 98: 227-237.

[1]	GUO Zhi-ben, TANG Wen-cai, LI Xiao-hua, TANG Fu-qiang, ZHANG Wei-lan. Application of three-dimensional CT reconstruction in the evaluation of tumor volume of hepatocellular carcinoma before hepatectomy [J]. Chinese Hepatolgy, 2021, 26(9): 1003-1006.
[2]	CHEN Chao, YAO Ling, QIU Bang-dong, WANG Xiao-yan. Serum GP73 and hepcidin levels are corelated with the prognosis of hepatitis B-related liver cancer patients [J]. Chinese Hepatolgy, 2021, 26(9): 1007-1010.
[3]	YUAN Yi-ran, CHEN Long, ZHANG Zhen. miR-548a-5p regulates the apoptosis of hepatocellular carcinoma cell line HepG2 by targeting HMBOX1 [J]. Chinese Hepatolgy, 2021, 26(8): 871-873.
[4]	HOU Ya-ping, ZHANG Xiao-jing, LI Ting. The relationship between the expression of LncRNA-MEG3 and clinicopathological features, prognosis of patients with primary liver cancer [J]. Chinese Hepatolgy, 2021, 26(7): 757-760.
[5]	LV Fa-kai, WANG Deng-ji, XIE Yu-hui, ZHANG Yu. Effect of CLCVP during complex laparoscopic hepatectomy on perioperative indicators and prognosis in patients with hepatocellular carcinoma [J]. Chinese Hepatolgy, 2021, 26(7): 761-764.
[6]	AI Jun, ZHANG Jia-juan, ZHENG Wen-kai, LI Ping. Correlation between ABO blood type and risk of liver cancer: a meta-analyses [J]. Chinese Hepatolgy, 2021, 26(7): 765-769.
[7]	ZHAO Kai, XUE Jin-feng, XUE Peng-fei, CHANG Peng. Effect of apatinib on angiogenic factors of patients with advanced unresectable hepatocellular carcinoma after transarterial chemoembolization [J]. Chinese Hepatolgy, 2021, 26(6): 628-631.
[8]	JIA Zhe, ZHANG Ke, HUANG Rong-hai, HE Rong, LU Yan, JIANG Li. The study of cellular immune function and its clinical significance in patients with liver cancer combined with liver cirrhosis and hypersplenism [J]. Chinese Hepatolgy, 2021, 26(6): 632-637.
[9]	YANG Qing-xi, SU Ji-liang, SUN Zhong-wen, LIU Yuan-xun, HU Wen-juan. Clinical characteristics of 21 liver cancer patients complicated with cerebral infarction [J]. Chinese Hepatolgy, 2021, 26(6): 642-645.
[10]	LI Fei-long, ZHANG Zi-qian. A study about the potential influencing factors for short-term mortality risk of metastatic liver cancer complicated with hepatic encephalopathy [J]. Chinese Hepatolgy, 2021, 26(6): 646-649.
[11]	LIAO Xin-ai, FENG Hui-juan, ZHUO Chuan-shang, YE Zhi, LIU Li-juan. Detection and clinical significance of mitochondrial DNA content in peripheral blood mononuclear cells of patients with primary liver cancer [J]. Chinese Hepatolgy, 2021, 26(5): 514-517.
[12]	WANG Chuang-sheng, SUN Jie, SHI Jia. Effect of water isolation technology in MWA treatment for primary liver cancer on the 3-year prognosis of patients [J]. Chinese Hepatolgy, 2021, 26(5): 527-529.
[13]	SHEN Yu, WAN Wei, LI Quan-xi, WU Xing-xing. The influence of different degrees of cirrhosis on the prognosis of patients with hepatitis B virus-associated hepatocellular carcinoma [J]. Chinese Hepatolgy, 2021, 26(5): 530-533.
[14]	JI Xiao-mei, SHAO Chun-yan, JI Hao-ming, GHAO Chun-yan. Effect of sequential treatment of human albumin on liver function and prognosis in patients with primary liver cancer complicated with cirrhosis after radiofrequency ablation [J]. Chinese Hepatolgy, 2021, 26(5): 534-537.
[15]	DONG Xiao-feng, YANG Ying-hao, ZHANG Yan, WANG Jian-bin, ZHU Xiao-hong, LIU Da-da, LIANG Dong. Current status for the treatment of primary liver cancer and an exploration of multidisciplinary team model [J]. Chinese Hepatolgy, 2021, 26(3): 262-265.